Funding
Hier finden Sie eine Übersicht der laufenden Drittmittel der AG Fuchs.
Sie befinden sich hier:
Currently funded projects
EU, ENDOSCAPE (coordinator):
A clinically applicable non-viral gene delivery technology (Horizon 2020, no. 825730)
DFG:
Anti-inflammatory glycosides from plants: Identification of cellular targets and examination of structure–function relationships (FU 408/11-1)
Aglaia Oncology Fund II:
Saponin-mediated endosomal escape enhancer technology for controlled intracellular drug delivery
Sonnenfeldstiftung:
Triterpenoids for controlled cytosolic drug release of targeted tumor therapeutics
Formerly funded projects (selection):
DFG:
Controlled efficacy increase of tumor-specific toxins by pH-dependent release of saponins from targeted nanoparticles
DFG:
Development of tumor-activated targeted toxins and their investigation in combination with glycosylated triterpenoids
DFG:
Saponin-mediated intracellular liberation of chimeric toxins. A new basic technology for cell-targeted tumor therapy
DFG:
Regulated intramembrane proteolysis of transferrin receptor 1 and the role of the released intracellular domain in signaling of iron metabolism
DFG:
Development of a novel strategy for cancer therapy by combining chimeric adapter toxins and triterpenoids investigated on mammary gland tumors
DFG:
Identification and characterization of the Arg-100-transferrin receptor shedding protease
Wilhelm-Sander-Stiftung:
Saporin/saponin transport systems for targeted release of drugs for tumor therapy
Deutsche José Carreras Leukämie-Stiftung:
Controlled intracellular release for increasing the efficacy of an antibody-based combination therapy of CD19/CD22 positive lymphoma and leukemia
Deutsche Krebshilfe:
Rekombinant fusions proteins for antibody-directed enzyme prodrug therapy (ADEPT) and radio-ADEPT of colon carcinoma
Sonnenfeldstiftung:
Generation of a modified apoptin with unique coupling sites for the development of a targeted toxin to induce tumor cell specific apoptosis